Genomics

Dataset Information

0

Patient-Derived Lung Cancer Organoid


ABSTRACT: Lung cancer shows substantial genetic and phenotypic heterogeneity across individuals, driving a need for personalized medicine. Here we report lung cancer organoids and normal bronchial organoids established from patients tissues comprising five histological subtypes of lung cancer and non-neoplastic bronchial mucosa as in vitro models representing individual patient. The lung cancer organoids recapitulate the tissue architecture of the primary lung tumours and maintain the genomic alterations of the original tumours during long-term expansion in vitro. The normal bronchial organoids maintain cellular components of normal bronchial mucosa. Lung cancer organoids respond to drugs based on their genomic alterations: a BRCA2 mutant organoid to olaparib, an EGFR mutant organoid to erlotinib, and an EGFR mutant/MET amplified organoid to crizotinib. Considering the short length of time from organoid establishment to drug testing, our newly developed model may prove useful for predicting patient-specific drug responses through in vitro patient-specific drug trials.

PROVIDER: EGAS00001003786 | EGA |

REPOSITORIES: EGA

Similar Datasets

2018-11-17 | E-MTAB-6023 | biostudies-arrayexpress
2015-05-07 | E-GEOD-64392 | biostudies-arrayexpress
| 2385953 | ecrin-mdr-crc
2019-11-26 | GSE119004 | GEO
2020-11-01 | GSE106850 | GEO
2023-04-19 | E-MTAB-12557 | biostudies-arrayexpress
2015-05-07 | E-GEOD-65253 | biostudies-arrayexpress
2022-09-30 | GSE189155 | GEO
2021-06-02 | PXD025397 | Pride
2018-12-04 | GSE99583 | GEO